NASDAQ:DCTH Delcath Systems (DCTH) Stock Price, News & Analysis $9.67 -0.78 (-7.46%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$9.52▼$10.4250-Day Range$7.36▼$11.0052-Week Range$2.25▼$11.74Volume492,080 shsAverage Volume255,910 shsMarket Capitalization$268.69 millionP/E RatioN/ADividend YieldN/APrice Target$21.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Delcath Systems alerts: Email Address Delcath Systems MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside124.1% Upside$21.67 Price TargetShort InterestHealthy5.25% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.29Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.33) to ($0.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.77 out of 5 starsMedical Sector389th out of 910 stocksSurgical & Medical Instruments Industry49th out of 95 stocks 3.5 Analyst's Opinion Consensus RatingDelcath Systems has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDelcath Systems has only been the subject of 3 research reports in the past 90 days.Read more about Delcath Systems' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.25% of the outstanding shares of Delcath Systems have been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Delcath Systems has recently decreased by 7.59%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDelcath Systems does not currently pay a dividend.Dividend GrowthDelcath Systems does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DCTH. Previous Next 2.9 News and Social Media Coverage News SentimentDelcath Systems has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Delcath Systems this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for DCTH on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat Follows5 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Delcath Systems insiders have not sold or bought any company stock.Percentage Held by Insiders17.94% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.12% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Delcath Systems' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Delcath Systems are expected to grow in the coming year, from ($1.33) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Delcath Systems is -3.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Delcath Systems is -3.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDelcath Systems has a P/B Ratio of 64.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Delcath Systems' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Gold RepublicChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide. About Delcath Systems Stock (NASDAQ:DCTH)Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Read More DCTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DCTH Stock News HeadlinesAugust 30, 2024 | msn.com'This Is A Very Speculative Situation,' Jim Cramer On ADMA BiologicsAugust 29, 2024 | markets.businessinsider.comStrong Buy Rating for Delcath Systems Supported by High Efficacy and Safety of CHEMOSAT PlatformSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 28, 2024 | finance.yahoo.comDelcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 28, 2024 | finance.yahoo.comDelcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma PatientsAugust 27, 2024 | markets.businessinsider.comDelcath Systems (DCTH) Receives a Buy from Craig-HallumAugust 27, 2024 | marketwatch.comDelcath Systems Shares Hit 52-Week High After Tumor Study ResultsAugust 27, 2024 | seekingalpha.comDelcath stock jumps 15% on Hepzato Kit study publicationSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 27, 2024 | finance.yahoo.comDelcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma PatientsAugust 27, 2024 | markets.businessinsider.comDelcath Systems Reports Promising Results From Independent Study On PHP For Uveal MelanomaAugust 27, 2024 | finance.yahoo.comDelcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver TumorsAugust 23, 2024 | seekingalpha.comUndercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey EnergyAugust 20, 2024 | finance.yahoo.comDelcath Systems Announces Poster Presentation at the 2024 ESMO CongressAugust 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Delcath Systems Amidst Strong Hepzato Launch and Promising Future ProspectsAugust 12, 2024 | finance.yahoo.comDelcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 11, 2024 | finance.yahoo.comAnalysts' Revenue Estimates For Delcath Systems, Inc. (NASDAQ:DCTH) Are Surging HigherAugust 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Delcath Systems Amid Strong Financial Results and Market ExpansionSee More Headlines Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:DCTH CUSIPN/A CIK872912 Webdelcath.com Phone212-489-2100Fax212-489-2102Employees60Year FoundedN/APrice Target and Rating Average Stock Price Target$21.67 High Stock Price Target$25.00 Low Stock Price Target$18.00 Potential Upside/Downside+124.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,680,000.00 Net Margins-474.22% Pretax Margin-474.22% Return on Equity-312.48% Return on Assets-118.65% Debt Debt-to-Equity RatioN/A Current Ratio2.55 Quick Ratio2.04 Sales & Book Value Annual Sales$11.88 million Price / Sales22.62 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book64.47Miscellaneous Outstanding Shares27,786,000Free Float22,801,000Market Cap$268.69 million OptionableOptionable Beta0.78 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Gerard J. Michel MBA (Age 61)MS, CEO & Director Comp: $727.97kMs. Sandra Pennell (Age 44)Senior VP of Finance and Principal Financial & Accounting Officer Dr. Martha S. Rook Ph.D. (Age 54)Chief Operating Officer Mr. David HoffmanGeneral Counsel, Corporate Secretary & Chief Compliance OfficerDr. Johnny John M.D. (Age 59)Senior Vice President of Clinical Operations & Medical Affairs Comp: $472.16kDr. Vojislav Vukovic M.D. (Age 57)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsBrainsWayNASDAQ:BWAYApollo EndosurgeryNASDAQ:APENBioLife SolutionsNASDAQ:BLFSAvanos MedicalNYSE:AVNSSilk Road MedicalNASDAQ:SILKView All CompetitorsInsiders & InstitutionsShellback Capital LPBought 161,688 shares on 8/15/2024Ownership: 0.582%Marshall Wace LLPBought 6,066 shares on 8/14/2024Ownership: 0.334%Cubist Systematic Strategies LLCBought 44,222 shares on 8/14/2024Ownership: 0.159%Renaissance Technologies LLCBought 82,900 shares on 8/9/2024Ownership: 0.298%Levin Capital Strategies L.P.Sold 39,969 shares on 8/7/2024Ownership: 0.054%View All Insider TransactionsView All Institutional Transactions DCTH Stock Analysis - Frequently Asked Questions How have DCTH shares performed this year? Delcath Systems' stock was trading at $4.16 at the start of the year. Since then, DCTH stock has increased by 132.5% and is now trading at $9.67. View the best growth stocks for 2024 here. How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (NASDAQ:DCTH) issued its earnings results on Monday, August, 5th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.12. The firm earned $7.77 million during the quarter, compared to analyst estimates of $5 million. Delcath Systems had a negative net margin of 474.22% and a negative trailing twelve-month return on equity of 312.48%. When did Delcath Systems' stock split? Shares of Delcath Systems reverse split on the morning of Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Delcath Systems' major shareholders? Top institutional investors of Delcath Systems include Rosalind Advisors Inc. (9.54%), AIGH Capital Management LLC (8.64%), Shellback Capital LP (0.58%) and Legato Capital Management LLC (0.42%). Insiders that own company stock include Gil Aharon, Rosalind Advisors, Inc, Gerard J Michel, Vojo Vukovic, John Purpura, Sandra Pennell, Steven A J Salamon and John Richard Sylvester. View institutional ownership trends. How do I buy shares of Delcath Systems? Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DCTH) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Delcath Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DCTH Stock Alerts